Transforming immune cells to fight cancer more effectively
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10774241
This study is testing a new way to help your immune system fight cancer better by using special antibodies that keep certain inflammatory cells from reaching tumors and encourage them to attack cancer cells more strongly, which could make cancer treatments work even better for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10774241 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new method to enhance the immune response against tumors by targeting specific receptors on inflammatory cells. The approach involves creating specialized antibodies that not only prevent these cells from migrating to tumors but also reprogram them to attack cancer cells more aggressively. By blocking multiple sites on the CCR2 receptor, the researchers aim to improve the effectiveness of cancer treatments and reduce tumor growth. Patients may benefit from this innovative strategy that combines drug delivery with immune modulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer or other malignancies that may benefit from enhanced immune responses.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not express the CCR2 receptor may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors.
How similar studies have performed: Other research has shown promise in using immune modulation strategies to enhance cancer therapies, indicating that this approach may be viable.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NGUYEN, JULIANE — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: NGUYEN, JULIANE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, Breast Cancer